文献速递前列腺癌

多参数磁共振成像单独用于前列腺癌主动监测不足以检测分级重新分类

Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
PubMed 文献 · Eur Urol · 2020-07-04

该研究评估多参数磁共振成像(mpMRI)能否替代主动监测(AS)中的活检,发现166例男性在中位29个月时升级,mpMRI总体阴性预测值为79.5%,前列腺特异性抗原密度≥0.15 ng/ml/cm3者仅65.5%,提示mpMRI单独不足以排除病理重新分类。

要点

  • mpMRI总体阴性预测值79.5%,不足以安全替代监测活检。
  • PSA密度≥0.15 ng/ml/cm3者mpMRI阴性预测值降至65.5%。
  • 确诊活检或其他风险因素存在时,mpMRI漏诊风险更高。

核心结论

  • mpMRI有助于检测临床显著前列腺癌,但单独使用不足以排除病理重新分类,尤其在确诊活检或存在其他风险因素时。

研究设计与样本

  • 研究纳入接受主动监测的低风险前列腺癌男性,评估mpMRI对分级重新分类的阴性预测值。

主要发现

  • 166例男性在中位29个月(四分位距13-54)时升级。
  • mpMRI总体阴性预测值为79.5%,至第四次监测活检范围为74.4%至84.6%。
  • PSA密度≥0.15 ng/ml/cm3者,mpMRI总体阴性预测值为65.5%,系列扫描范围为57.1%至73.3%。

临床怎么用

  • mpMRI不能安全替代主动监测中的前列腺活检,尤其确诊活检或存在其他风险因素时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiparametric magnetic resonance imaging (mpMRI) has improved the detection of clinically significant prostate cancer. It remains unclear, however, whether mpMRI can safely replace confirmatory or surveillance biopsies in men with low-risk disease managed with active surveillance (AS). Overall, 166 men were upgraded at a median of 29 mo (interquartile range 13-54). The overall negative predictive value (NPV) of mpMRI was 79.5% and ranged from 74.4% to 84.6% for all AS biopsies up to the fourth surveillance biopsy. In men with prostate-specific antigen density ≥0.15 ng/ml/cm3, the overall NPV of mpMRI was 65.5% and ranged from 57.1% to 73.3% across serial mpMRI scans. These findings support the hypothesis that mpMRI is helpful but insufficient to rule out pathological reclassification, especially at confirmatory biopsy or in the presence of other risk factors. PATIENT SUMMARY: Multiparametric magnetic resonance imaging (mpMRI) alone misses a considerable percentage of clinically significant prostate cancers (Gleason grade group ≥2) in men on active surveillance for low-risk prostate cancer. We conclude that mpMRI alone cannot safely replace surveillance prostate biopsies, particularly at confirmatory biopsy or in the presence of other risk factors.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Chu CE, Lonergan PE, Washington SL, et al. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. Eur Urol. 2020. PMID: 32631744. doi:10.1016/j.eururo.2020.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。